Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban
Autore:
McCollam, PL; Lage, MJ; Bala, M;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, US Hlt Outcomes Grp, Indianapolis, IN 46285 USA Eli Lilly & Co Indianapolis IN USA 46285 Grp, Indianapolis, IN 46285 USA Centocor Inc, Malvern, PA 19355 USA Centocor Inc Malvern PA USA 19355Centocor Inc, Malvern, PA 19355 USA
Titolo Testata:
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
fascicolo: 2, volume: 54, anno: 2001,
pagine: 152 - 157
SICI:
1522-1946(200110)54:2<152:ACOTHC>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; GLYCOPROTEIN IIB/IIIA INHIBITION; LONG-TERM COST; BALLOON ANGIOPLASTY; ECONOMIC-ASSESSMENT; RANDOMIZED TRIAL; BLOCKADE; REVASCULARIZATION; OUTCOMES; HEPARIN;
Keywords:
hospital costs; multivariate analysis; retrospective study; sample selection model; glycoprotein IIb/IIIa antagonists;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: McCollam, PL Eli Lilly & Co, Lilly Corp Ctr, US Hlt Outcomes Grp, Indianapolis, IN 46285 USA Eli Lilly & Co Indianapolis IN USA 46285 polis, IN 46285 USA
Citazione:
P.L. McCollam et al., "A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban", CATHET C IN, 54(2), 2001, pp. 152-157

Abstract

The purpose of this study was to examine the total hospital costs associated with the receipt of abciximab versus tirofiban for percutaneous coronaryintervention (PCI) patients. Hospital billing data for patients with a primary procedure of PCI was examined for the period of July 1998 to June 1999from HCIA-Sach's Clinical Pathways Database. Data were analyzed for all patient discharges whose records indicated use of abciximab or tirofiban witha PCI. Results are reported for 3,967 patients. Multivariate analysis was used to control for a wide range of factors (GP IIb/IIIa selection, patientdemographics, stent use, insurance type, health conditions, admission information, and hospital characteristics) that may influence the cost of hospitalization. A two-stage sample selection model was used to estimate total costs. The first stage of the analysis utilizes a probit regression to determine the factors associated with the likelihood of receiving abciximab versus tirofiban. The second stage of the analysis examines the factors associated with total hospital costs, while controlling for unobserved factors that may be correlated with the patient's likelihood of receiving abciximab. The mean unadjusted cost per hospitalization, including drug costs, was $10,762 (abciximab $10,813 and tirofiban $10,567). After controlling for high-risk indications and selection bias with the two-stage sample selection model, results indicate there was no significant difference in costs associatedwith the receipt of abciximab versus tirofiban. However, the results also indicate that the two-stage sample selection model may not be needed (X wasnot statistically significant) hence, the cost equation was reestimated using ordinary least-squares methodology (OLS). In the OLS analysis, receipt of abciximab versus tirofiban was associated with a significant reduction in costs ($470 reduction; P = 0.05). This study uses realworld data to examine the total hospital costs for PCI patients who receive abciximab versus tirofiban. Results of the two-stage sample selection model indicate there isno difference in total hospital costs (including drug costs) between abciximab- and tirofiban-treated patients. If the results of the OLS model are considered, a slight decrease in total hospital costs is observed in abciximab recipients. Cost-containment strategies that focus on component costs may not lead to intended overall cost savings. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 04:05:27